Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Progress against solid tumors in danger: the metastatic breast cancer example.

Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN.

J Clin Oncol. 2012 Oct 1;30(28):3444-7. Epub 2012 Aug 27. No abstract available.

2.

Making genuine progress against metastatic breast cancer.

Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA.

J Clin Oncol. 2012 Oct 1;30(28):3448-51. Epub 2012 Aug 27. Review. No abstract available.

PMID:
22927527
3.

Pushing the envelope.

[No authors listed]

Nat Biotechnol. 2011 Aug 5;29(8):669. doi: 10.1038/nbt.1956. No abstract available.

PMID:
21822220
4.

Avastin saga reveals debate over clinical trial endpoints.

Sharma SP.

J Natl Cancer Inst. 2012 Jun 6;104(11):800-1. doi: 10.1093/jnci/djs265. Epub 2012 Jun 6. No abstract available.

5.

Reputation and precedent in the bevacizumab decision.

Carpenter D, Kesselheim AS, Joffe S.

N Engl J Med. 2011 Jul 14;365(2):e3. doi: 10.1056/NEJMp1107201. Epub 2011 Jun 27. No abstract available.

6.

FDA panel votes to pull Avastin in breast cancer, again.

Ratner M.

Nat Biotechnol. 2011 Aug 5;29(8):676. doi: 10.1038/nbt0811-676c. No abstract available. Erratum in: Nat Biotechnol. 2012 Feb;30(2):193.

PMID:
21822226
7.

FDA cancels approval for bevacizumab in advanced breast cancer.

Tanne JH.

BMJ. 2011 Nov 25;343:d7684. doi: 10.1136/bmj.d7684. No abstract available.

PMID:
22121166
8.

Changing end points in breast-cancer drug approval--the Avastin story.

D'Agostino RB Sr.

N Engl J Med. 2011 Jul 14;365(2):e2. doi: 10.1056/NEJMp1106984. Epub 2011 Jun 27. No abstract available.

9.

Avastin withdrawal symptoms.

Lynce F, Swain SM.

Expert Opin Pharmacother. 2012 Feb;13(3):293-8. doi: 10.1517/14656566.2012.652088. Epub 2012 Jan 21. No abstract available.

PMID:
22263961
10.

FDA. Once on 'fast track,' avastin now derailed.

Couzin-Frankel J, Ogale Y.

Science. 2011 Jul 8;333(6039):143-4. doi: 10.1126/science.333.6039.143. No abstract available.

PMID:
21737712
11.

Avastin hearing leads to more uncertainty over drug's future.

Goozner M.

J Natl Cancer Inst. 2011 Aug 3;103(15):1148-50. doi: 10.1093/jnci/djr293. Epub 2011 Jul 18. No abstract available.

12.

Avastin for breast cancer, 2005-2011: requiescat in pacem?

Burstein HJ.

J Natl Compr Canc Netw. 2011 Dec;9(12):1321-3. No abstract available.

PMID:
22157551
13.

Is the battle over bevacizumab coverage looming?

Larkin C.

J Natl Compr Canc Netw. 2011 Mar;9(3):261-3. No abstract available.

PMID:
21393437
14.

Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint.

Robert NJ.

Breast Cancer Res Treat. 2010 Jul;122(1):9-10. doi: 10.1007/s10549-010-0919-7. Epub 2010 May 22. No abstract available.

PMID:
20495865
15.

Bevacizumab recommendation highlights difficulties.

Printz C.

Cancer. 2011 Nov 15;117(22):5025. doi: 10.1002/cncr.26642. No abstract available.

16.

FDA pulls approval for avastin in breast cancer.

Rose S.

Cancer Discov. 2011 Dec;1(7):OF1-2. doi: 10.1158/2159-8290.CD-ND112311OL-08. Epub 2011 Nov 23.

17.

Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Montero AJ, Escobar M, Lopes G, Glück S, Vogel C.

Curr Oncol Rep. 2012 Feb;14(1):1-11. doi: 10.1007/s11912-011-0202-z. Review.

18.

FDA committee votes to withdraw bevacizumab for breast cancer.

Lenzer J.

BMJ. 2011 Jul 5;343:d4244. doi: 10.1136/bmj.d4244. No abstract available.

PMID:
21729988
19.

Avastin's uncertain future in breast cancer treatment.

Twombly R.

J Natl Cancer Inst. 2011 Mar 16;103(6):458-60. doi: 10.1093/jnci/djr088. Epub 2011 Mar 10. No abstract available.

20.

US Food and Drug Administration approval overview in metastatic breast cancer.

Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R.

J Clin Oncol. 2012 May 10;30(14):1705-11. doi: 10.1200/JCO.2011.39.2613. Epub 2012 Mar 19. Review. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk